Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, UK.
Blood. 2011 Aug 25;118(8):2174-83. doi: 10.1182/blood-2011-02-334326. Epub 2011 Jun 28.
CD160 is a human natural killer (NK)-cell-activating receptor that is also expressed on T-cell subsets. In the present study, we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated CD160 expression in 98% (590 of 600) of chronic lymphocytic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle cell lymphoma (MCL) in the leukemic phase, and 16% (23 of 145) of other B-LPD cases. CD160 transcript and protein were absent in the normal B-cell hierarchy, from stem cells, B-cell precursors, maturing B cells in the germinal center, and circulating B cells, including CD5(+)CD19(+) B1 cells in umbilical cord. CD160 positivity was significantly higher in CLL and HCL in terms of percentage (65.9% and 67.8%, respectively, P < .0001) and median fluorescence intensity (552 and 857, respectively, P < .0001) compared with all other B-LPD cases. Lymph node CLL samples were also CD160(+). Using the disease-specific expression of CD5, CD23, and CD160, a score of 3 characterized CLL (diagnostic odds ratio, 1430); a score of 0 excluded CLL, MCL, and HCL; and the CD23/CD5 ratio differentiated CLL from leukemic CD23(+) MCL. In the B-cell lineage, CD160 is a tumor-specific antigen known to mediate cellular activation signals in CLL, and is a novel target for therapeutic manipulation and monitoring of minimal residual disease.
CD160 是一种人类自然杀伤 (NK) 细胞激活受体，也表达于 T 细胞亚群。本研究检测了 811 例连续的 B 细胞淋巴增殖性疾病 (B-LPD)，结果显示 CD160 在 98% (590/600) 的慢性淋巴细胞白血病 (CLL) 病例、100% (32/32) 的毛细胞白血病 (HCL) 病例、白血病期的 15% (5/34) 套细胞淋巴瘤 (MCL) 和 16% (23/145) 的其他 B-LPD 病例中表达。CD160 转录本和蛋白在正常 B 细胞谱系中缺失，包括从干细胞、B 细胞前体、生发中心成熟的 B 细胞和循环 B 细胞，包括脐带血中的 CD5(+)CD19(+)B1 细胞。与所有其他 B-LPD 病例相比，CLL 和 HCL 的 CD160 阳性率（分别为 65.9%和 67.8%，P<.0001）和中位荧光强度（分别为 552 和 857，P<.0001）均显著更高。淋巴结 CLL 样本也为 CD160(+)。利用 CD5、CD23 和 CD160 的疾病特异性表达，3 分特征性地确定为 CLL（诊断优势比，1430）；0 分排除 CLL、MCL 和 HCL；CD23/CD5 比值可区分 CLL 与白血病性 CD23(+)MCL。在 B 细胞谱系中，CD160 是一种肿瘤特异性抗原，已知可在 CLL 中介导细胞激活信号，是治疗干预和监测微小残留病的新靶点。
